1. Looking Beyond HIV Infection: CCR5 Blockade as an Immunomodulatory Concept 

2. Introduction

3. Inflammation-Associated Disease in HIV-Infected Adults

4. SMART Trial*: Markers of Inflammation and Coagulation Associated With Increased Mortality

5. Multifactorial Mechanisms Driving Systemic Immune Activation in Chronic HIV Infection

6. Therapeutic Agents Evaluated in HIV for Their Effect on Immune Activation

7. Mediators of Inflammation: CCR5

8. Clinical Trials Evaluating CCR5 Antagonism in Non-HIV-Infected Patients

9. CCR5 Antagonism in the Treatment of RA

10. CCR5 Blockade in the Prevention of GVHD

11. CCL5/CCR5 Interactions in Cancer

12. Maraviroc: CCR5 Antagonist for the Treatment of HIV

13. CCR5 Blockade for Neuroinflammatory Diseases

14. Effects of Maraviroc Treatment on CIMT in HIV-1/HCV Coinfected Patients

15. CADIRIS Study: CCR5 Antagonism Failed to Decrease IRIS in HIV Infection

16. Maraviroc Intensification of cART in Patients With Suboptimal Immunologic Recovery

17. HIV: An Inflammatory Disease

18. Conclusions

19. Abbreviations

20. Abbreviations (cont)